Development and validation of HPTLC method for the analysis of Olmutinib in Bulk drug

Balu S. Khandare

1Kasturi Shikshan Sanstha College of Pharmacy Shikrapur Pune, Maharashtra, India-412208

Abstract: This paper describes a simple, precise, rapid and accurate high-performance thin layer chromatographic (HPTLC) method for determination of Olmutinib in bulk drug. Chromatographic separation was performed on aluminium plates precoated with silicagel60F254 as the stationary phase using solvent system consisted of chloroform: methanol (9:1v/v). After the application of bands using CAMAG Automatic TLC Sampler 4, the plate was developed in the solvent system up to 70 mm in CAMAG T win Trough Chamber. This solvent system was found to give compact spot for Olmutinib with Rf value of 0.32±0.02. The spots were scanned at 267.68nm. The calibration curves were linear with correlation coefficient of 0.995 for Olmutinib. Linear regression analysis showed good linearity in the concentration range of 100-1100 ng per spot. The method was validated in terms of Precision, specificity, and Linearity. The average recovery of the standards in the samples was found to be 99.65% at the same time we have checked the C.V. values of Reproducibility, intra-day and inter-day tabulated further. The proposed method can be successfully applied to determine the drug content of bulk drug.

Keyword: HPTLC, Olmutinib, silica gel, Linearity, Specificity, Precision.

Introduction:

Epidermal growth factor binds with high affinity to epidermal growth factor receptor (EGFR) upon cell surface, activates the intrinsic protein-tyrosine kinase activity of receptor, initiating signal transduction cascade results in various biochemical changes in the cell - rises calcium levels, increased protein synthesis and increases expression of certain genes. Eg.gene of EGFR leads to DNA synthesis and cell proliferation. Mutations of EGFR expressions or activity results are in cancer. Olmutinib N-(3-((2-(4-(4-methylpiperazin-1-yl)phenyl)aminoo)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide.

Olmutinib is an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) of third generation which is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd to treat non-small-cell lung cancer (NSCLC). Olmutinib binds covalently and inhibits activating EGFR mutations and overcoming T790M resistance mutation (mutation of epidermal growth factor receptor).

Balu S. Khandare /International Journal of PharmTech Research, 2020,13(1): 37-43.

DOI: http://dx.doi.org/10.20902/IJPTR.2019.130105
In the present study, we developed a novel analytical method and validation of first derivative method for Olmutinib in bulk using UV spectroscopy. The method was validated in accordance with the guidelines of the International Conference on Harmonization (ICH).

Literature survey reveals that a few spectrophotometric, RP-HPLC methods are reported for the estimation of Olmutinib in combination with other drugs.  

![Figure 01: Chemical Structure of Olmutinib](image)

**Experimental:**

**Instruments and Apparatus:** HPTLC plates pre-coated with aluminium plate 60F<sub>254</sub> plates (100×100 mm) with 250 µm thickness (E. Merk, Darmstadt, Germany), supplied by Anchrom technologist, Mumbai using a Camag Linomat V. Densitometry was carried out with a CAMAG TLC Scanner 3, fitted with a win-CATS 1.4.0 planar chromatography manager software. Samples were applied to the HPTLC plates using the spray-on technique of CAMAG LINOMAT V under nitrogen gas flow, and developed in a CAMAG 10 cm 10 cm twin trough chambers.

**Chemicals and reagents:** The Olmutinib was supplied as a gift sample by Mylan laboratories Pvt. Ltd. Hyderabad (India). The pure drug obtained had 99.9% w/w assay value, and was used without further purification. All the solvents used were either analytical or HPLC grade.

**Chromatographic Conditions:**

Before analysis, HPTLC plates were cleaned by pre-development with methanol and activated at 110°C for 5 min for solvent removal. Analysis was performed on silica gel precoated aluminium plate 60 F254, 20 × 10 cm. The samples were applied to the plates as bands that were 6 mm wide and 10 mm a part by means of a Camag Linomat V sample applicator. Automatic spotter equipped with a 10µL syringe and operated with settings of band length, 8 mm; distance between bands, 10 mm; distance from the plate edge,10mm; and distance from the bottom of the plate, 10 mm. The chamber saturation time with mobile phase was 20 min. The plates were developed in a Camag twin trough glass chamber with prior saturation of 30 min with the mobile phase. The mobile phase consisted of Chloroform: Methanol (9:1v/v). After development, plates were allowed to dry and were observed under Camag TLC Visualizer. Densitometric scanning was performed using a Camag TLC scanner 4 in the reflectance absorbance mode at 267.68nm for all measurements and operated by the WINCAT’S software version 2.0. The source of radiation used was a deuterium lamp emitting a UV spectrum between 190 and 900nm.

**Preparation of Standard Solution:**

Accurately weighed and transferred 10 mg of API (Olmutinib) working standard into a 10 ml cleaned and dried volumetric flask and dissolved in 10 ml of chloroform: methanol(9:1)to it and sonicate it for 15 mins. The solution with the concentration of 1mg/ml is prepared. Further concentration of 0.1mg/ml is prepared by Pipetting out 1mL from the above prepared stock solution and transferring into 10mL of volumetric flask and volume is adjusted. The concentration of this solution is 0.1mg/mL. Pipette out 1ml of the above solution and add 9ml of mixture of chloroform: methanol(9:1).The concentration of this solution is 0.01mg/ml.
Preparation of sample solution:

Tablets were accurately weighed and trituated to a fine powder. The average weight of the tablet powder was transferred into a 50ml standard volumetric flask. 40ml mixture of chloroform: methanol (9:1) was added to it and sonicated for 15mins. The concentration of this solution is 1mg/ml. Pipette out 1ml of the above solution in a 10 ml standard volumetric and adds 9 ml of mixture of chloroform: methanol (9:1). The concentration of this solution is 0.1mg/ml. Pipette out 1ml of the above solution in a 10 ml standard volumetric and add 9 ml of mixture of chloroform: methanol (1:4). The concentration of this solution is 0.01mg/ml.

Method Validation:

As per the ICH guidelines, the method validation parameters were checked for Identification, Precision, specificity, and Linearity. The present method was validated according to the ICHQ2(R1) guidelines. The linearity was determined by using working standard solutions between 100-1100 ng/spot. The spectrums of these solutions were recorded at wavelength 267.68nm A calibration curve was constructed by taking concentrations on X axis and absorbance of standards on Y-axis and regression equation was obtained. Repeatability study was carried out by preparing aminium 6 determinations of standard solution of Olmutinib and analysed by Camag scanner and absorbance was recorded at 267.68 nm Relative standard deviation (%RSD) was calculated.

Precision (In intra-day and inter-day) with 6 concentrations of Olmutinib working standard were analyzed 3 on the same day and 3 on next day. The results were reported in terms of percentage relative standard deviation (%RSD). For LOD and LOQ nine sets of known concentrations (0.00-0.004 μg/spot) were prepared. Calibrationcurveswereplottedforeachset.LODandLOQwerecalculatedusing the regression equation and following formulaeas;

\[
\text{LOD} = 3.3 \frac{\text{SD}}{S} \quad \text{LOQ} = 10 \frac{\text{SD}}{S}
\]

Where,

\(\text{SD} = \) is standard deviation of y-intercept of the calibration curves.

\(S = \) is mean slope of five calibration curves.

The accuracy of the method was determined by calculating recoveries of Olmutinib by the standard addition method. Known amount of Olmutinib at 80 %, 100 %, 120 % were added to a pre quantified sample solution. Each level of accuracy was carried out in a triplicate. The mean of the recoveries at 80%, 100%, and 120% levels were estimated by applying the obtained values to the regression equation of the calibrationcurve.

Results and Discussion:

These method developed was proceeding with wavelength selection. The optimized wavelength was 267.68nm.In order to get the optimized HPTLC method various mobile phases were used. The mobile phase consisted of an aqueous solution of chloroform: methanol (9:1 v/v) was used and the Rf value was about 0.32. The specificity of the method was determined for presence of components that may be unexpected to be present. The absence of additional peaks in the chromatogram indicates non-interference of the excipients in the tablet dosage form. The linearity was determined in analyte concentration range of 100-1100 ng per spot. The calibration curve obtained by plotting concentration versus absorbance was linear and the correlation coefficient was found to be 0.995 for Olmutinib (Table 1, Fig. 2). The precision of the method was ascertained from determinations of peak areas of six replicates of sample solution. The repeatability, interday and intraday was calculated for Olmutinib(Table 2). The accuracy study was performed in 80%, 100% and 120%. The percentage recovery was determined and was found to be 99.12% (Tables 3).

The LOD and LOQ were calculated as 0.50 ng/spot and 2.9 ng/spot respectively (Table 4).
Table no.1: Results for Linearity of Olmutinib

| Concentration | Absorbance |
|---------------|------------|
| 100           | 0.195      |
| 300           | 0.290      |
| 500           | 0.340      |
| 700           | 0.447      |
| 900           | 0.522      |
| 1100          | 0.605      |

Figure 2: Calibration Curve of Olmutinib

Figure 3: Graph of Rf value olmutinib band run sample

Figure 4: Graph of Rf value olmutinib band
Figure 5: Method developed Rf value Olmutinib peak

Table no. 2: Results for Precision of Olmutinib

| RF value | Peak Area  | Deviation | CV  | Average Area |
|----------|------------|-----------|-----|--------------|
| 0.347    | 0.00988    | 2.41%     |     |              |
| 0.337    | 0.00969    | 0.47%     |     |              |
| 0.334    | 0.00940    | -2.50%    |     |              |
| 0.324    | 0.00952    | -1.33%    |     |              |
| 0.326    | 0.00974    | 0.96%     |     |              |
|          |            |           | 1.94% | 0.010        |

Intraday

| RF value | Peak Area  | Deviation | CV  | Average Area |
|----------|------------|-----------|-----|--------------|
| 0.360    | 0.00655    | 1.66%     |     |              |
| 0.355    | 0.00623    | -3.29%    |     |              |
| 0.353    | 0.00641    | -0.54%    |     |              |
| 0.345    | 0.00644    | -0.08%    |     |              |
| 0.348    | 0.00659    | 2.25%     |     |              |
|          |            |           | 2.18% | 0.006        |

Interday

| RF value | Peak Area  | Deviation | CV  | Average Area |
|----------|------------|-----------|-----|--------------|
| 0.315    | 0.00970    | 1.19%     |     |              |
| 0.308    | 0.00947    | -1.24%    |     |              |
| 0.305    | 0.00955    | 0.36%     |     |              |
| 0.308    | 0.00946    | -1.27%    |     |              |
| 0.311    | 0.00975    | 1.69%     |     |              |
|          |            |           | 1.38% | 0.010        |

Figure 6: Olmutinib graph of Intraday Precision
Table no. 3: Results for Accuracy Studies of Olmutinib

| Concentration taken in µg/spot (A) | Standard addition in µg/spot (B) | Total drug Concentration (µg/spot) (A+B) | Area     | Average | Recovery % | Mean     |
|-----------------------------------|----------------------------------|----------------------------------------|----------|---------|------------|----------|
| 100                              | 80                               | 18 0                                   | 5321     | 5354.33 | 106.411    | 99.12    |
|                                  |                                  |                                        | 5332     |          |            |          |
|                                  |                                  |                                        | 5410     |          |            |          |
| 100                              | 100                              | 20 0                                   | 5601     | 5706.66 | 100.590    | 99.12    |
|                                  |                                  |                                        | 5620     |          |            |          |
|                                  |                                  |                                        | 5899     |          |            |          |
| 100                              | 120                              | 22 0                                   | 6259     | 6267.66 | 93.746     |          |
|                                  |                                  |                                        | 6255     |          |            |          |
|                                  |                                  |                                        | 6289     |          |            |          |

Table no. 4: Results for LOD and LOQ

| Drug        | LOD | LOQ |
|-------------|-----|-----|
| Olmutinib   | 1.06| 3.66|

Conclusion:

The developed HPTLC procedure was found to be precise, specific and accurate. Statistical analysis indicated that the method was reproducible and selective for the analysis of Olmutinib in bulk drug and without interference from excipients. Hence, this method can be easily and conveniently adopted for routine analysis of Olmutinib in bulk and its pharmaceutical dosage forms.

Acknowledgements:

The authors are grateful to, the Principal and the Management of Kasturi Shikshan Sanstha’s college of Pharmacy Shikrapur Pune. The authors are thankful to Mylan laboratories pvt. Ltd., Hyderabad (India) for providing gift sample.

References:

1. Kim, E.S., 2016. Olmutinib: first global approval. *Drugs*, 76(11), pp.1153-1157.
2. Park, K., Lee, J.S., Lee, K.H., Kim, J.H., Cho, B.C., Min, Y.J., Cho, J.Y., Han, J.Y., Kim, B.S., Kim, J.S. and Lee, D.H., 2016. Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D. *J Clin Oncol*, 34(suppl), pp.abstr-9055.
3. Zhang, Z., Guo, X., To, K.K., Chen, Z., Fang, X., Luo, M., Ma, C., Xu, J., Yan, S. and Fu, L., 2018. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo. *Acta pharmaceutica sinica B*, 8(4), pp.563-574.

4. Attwa, M.W., Kadi, A.A., Darwish, H.W. and Abdelhameed, A.S., 2018. Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma. *RSC advances*, 8(70), pp.40387-40394.

5. B. Khandare, P.B. Dudhe, S. Upasani and M. Dhoke Spectrophotometric Determination of Vandetanib in Bulk by Area Under Curve and First Order Derivative Methods, International Journal of PharmTech Research, 2019, 12(02), 103-110.

6. Balu S. Khandare, Nikhil S. Bhujbal and Sandip S. Kshirsagar . Analytical Method Development and Validation of Vandetanib by Using RP-HPLC of Bulk Drug. Scholars Academic Journal of Pharmacy, 8(8): 432-435

7. ManojDhokeSachiUpasani, PrashikDudhe, BaluKhandare. Development and Validation of Adenosine by RP-HPLC Method in Bulk drug and Pharmaceutical dosage forms. Am. J. PharmTech Res, 2019,9(3), 240-246.

8. KHANDARE, B., Musle, A.C., Arole, S.S. and Popalghat, P.V., 2019. Analytical method development and validation of olmutinib bulk drug as per ICH Q2 guidelines by using RP-HPLC Method. *Journal of Drug Delivery and Therapeutics*, 9(4-A), pp.608-611.

9. KHANDARE, B., Musle, A.C., Arole, S.S. and Popalghat, P.V., 2019. Spectrophotometric Determination of Olmutinib in Bulk by Area under Curve and First Order Derivative Methods and its Validation as per ICH guidelines. *Journal of Drug Delivery and Therapeutics*, 9(4-A), pp.349-354.

10. Khandare, B.S. and Wagh, K.S., 2019. Formulation, Development and Evaluation of Fast Dissolving Oral Film of a Atenolol Drug and validation by RP-HPLC Method using ICH Q2 guidelines. *Journal of Drug Delivery and Therapeutics*, 9(5), pp.99-104.

11. Ouyang B, Zhou F, Zhen L, Peng Y, Sun J, Chen Q, Jin X, Wang G, Zhang J. simultaneous determination of tenofovirafenamide and its active metabolites tenofovir and tenofovirdisoproxilphosphate in Hbv-infected hepatocyte with a sensitive Lc–ms/ms method. Journal of pharmaceutical and biomedical analysis. 2017 Nov 30;146:147-53.

12. Bhirud CH, Hiremath SN. Development of validated stability-indicating simultaneous estimation of Tenofovirdisoproxilfumarate and emtricitabine in tablets by HPTLC. *Journal of Pharmacy Research*. 2013 Feb 1;7(2):157-61.

13. Prathipati PK, Mandal S, Destache CJ. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC–MS/MS and its application to a pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2016 Sep 10;129:473-81.

14. Akram NM, Umamahesh M. A New Validated RP-HPLC Method for the Determination of Emtricitabine and Tenofovir AF in its Bulk and Pharmaceutical Dosage Forms.

15. Redasani VK, Mali BJ, Surana SJ. Development and Validation of HPTLC Method for Estimation of SafinamideMesylate in Bulk and in Tablet Dosage Form. ISRN Analytical Chemistry. 2012 Apr 11;2012.

16. Rao NM, Bagyalakshmi J, Ravi TK. Development and validation of UV-Spectroscopic method for estimation of Voglibose in bulk and tablets. J Chem Pharm Res. 2010 May;2(2):350-56.

17. Sayana PS, Iyer RS, Shibi A, Harischandran S. Development and validation of HPTLC method for quantification of silodosin in bulk and pharmaceutical dosage form. The Pharma Innovation. 2012 Dec 1;1(10, Part A):60.

18. Shewiyo DH, Kaale E, Ugullum C, Sigonda MN, Risha PG, Dejaegher B, Smeyers–Verbeke J, Vander Heyden Y. Development and validation of a normal-phase HPTLC method for the simultaneous analysis of lamivudine, stavudine and nevirapine in fixed-dose combination tablets. Journal of pharmaceutical and biomedical analysis. 2011 Feb 20;54(3):445-50.

19. Shewiyo DH, Kaale EA, Risha PG, Dejaegher B, Smeyers-Verbeke J, Vander Heyden Y. HPTLC methods to assay active ingredients in pharmaceutical formulations: A review of the method development and validation steps. Journal of pharmaceutical and biomedical analysis. 2012 Jul 1;66:11-23.

*****